Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital public

Simple item page
dc.coverageDOI: 10.4067/S0034-98872021000901249
dc.creatorBenavente, Rafael
dc.creatorCida, Fernando
dc.creatorPuga, Bárbara
dc.creatorMolina, Javiera
dc.creatorBass, Francisca
dc.creatorAndrade, Alejandro
dc.creatorMonardes, Virginia
dc.creatorEncina, Andrea
dc.creatorCabrera, María Elena
dc.date2021
dc.date.accessioned2025-11-18T19:45:34Z
dc.date.available2025-11-18T19:45:34Z
dc.description<p>Background: Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome. Aim: To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material and Methods: All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis. Results: Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed. Conclusions: The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/57102cc2-b987-4f52-a563-69a6be3236b3
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/54037
dc.languagespa
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.149 (2021) nr.9 p.1249-1257
dc.subjectCohort Studies
dc.subjectImatinib
dc.subjectImatinib Mesylate
dc.subjectPhiladelphia Chromosome
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.titleQuimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital publicspa
dc.titleIntensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemiaeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE